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Shexiang Baoxin Pill (SBP) is an oral formulation of Chinese materia medica for the
treatment of angina pectoris. It displays pleiotropic roles in protecting the cardiovascular
system. However, the mode of action of SBP in promoting angiogenesis, and in particular
the synergy between its constituents is currently not fully understood. The combination of
ginsenosides Rb2 and Rg3 were studied in human umbilical vein endothelial cells
(HUVECs) for their proangiogenic effects. To understand the mode of action of the
combination in more mechanistic detail, RNA-Seq analysis was conducted, and
differentially expressed genes (DEGs), pathway analysis and Weighted Gene
Correlation Network Analysis (WGCNA) were applied to further identify important
genes that a play pivotal role in the combination treatment. The effects of pathway-
specific inhibitors were observed to provide further support for the hypothesized mode of
action of the combination. Ginsenosides Rb2 and Rg3 synergistically promoted HUVEC
proliferation and tube formation under defined culture conditions. Also, the combination of
Rb2/Rg3 rescued cells from homocysteine-induced damage. mRNA expression of
CXCL8, CYR61, FGF16 and FGFRL1 was significantly elevated by the Rb2/Rg3
treatment, and representative signaling pathways induced by these genes were found.
The increase of protein levels of phosphorylated-Akt and ERK42/44 by the Rb2/Rg3
combination supports the notion that it promotes endothelial cell proliferation via the PI3K/
Akt and MAPK/ERK signaling pathways. The present study provides the hypothesis that
SBP, via ginsenosides Rb2 and Rg3, involves the CXCR1/2 CXCL8 (IL8)-mediated PI3K/
Akt and MAPK/ERK signaling pathways in achieving its proangiogenic effects.
Edited by:
Giuseppe Valacchi,















Brain Tumor Center, Severance
Hospital, Yonsei University College of
Medicine, Seoul, South Korea
Mohamad Zobir SZ,
Malaysian Institute of Pharmaceuticals
and Nutraceuticals IPharm, National
Institutes of Biotechnology Malaysia,
Ministry of Science, Technology and
Innovation, Pulau Pinang, Malaysia
Nitin Sharma,
Department of Tumor Biology, Institute
for Cancer Research, The Norwegian
Radium Hospital, Oslo, Norway
Specialty section:
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 10 November 2020
Accepted: 11 January 2021
Published: 10 February 2021
Citation:
Choi RJ, Mohamad Zobir SZ,
Alexander-Dann B, Sharma N,
Ma MKL, Lam BYH, Yeo GSH,
Zhang W, Fan T-P and Bender A
(2021) Combination of Ginsenosides
Rb2 and Rg3 Promotes Angiogenic
Phenotype of Human Endothelial Cells




Abbreviations: SBP, shexiang baoxin pill; HUVECs, human umbilical vein endothelial cells; DEGs, differentially expressed
genes; WGCNA, weighted gene correlation network analysis; TCM, traditional Chinese medicine; CHD, coronary heart disease;
eNOS, endothelial nitric oxide synthase; MAPK, mitogen-activated protein kinase; GSEA, gene set enrichment analysis; HDFs,
human dermal fibroblasts; HCY, homocysteine
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 6187731
ORIGINAL RESEARCH
published: 10 February 2021
doi: 10.3389/fphar.2021.618773
Keywords: angiogenesis, tube formation, RNA-seq, weighted gene correlation network analysis, synergistic
combination, shexiang baoxin pill, ginsenoside Rb2, ginsenoside Rg3
INTRODUCTION
Shexiang Baoxin Pill (SBP) is a traditional Chinese medicine (TCM)
formulation taken orally to treat coronary heart disease (CHD) such
as chronic stable angina (Lu et al., 2018). Like many other traditional
medicines, SBP is derived from plant and animal products that
contain a multitude of components which are thought to contribute
to the holistic efficacy of the formulation (Yan et al., 2006; Yan et al.,
2009). SBP has previously been shown to be protective against
myocardial infarction (Wu et al., 2020) and associated oxidative
injury and inflammation in ratmodels (Xiang et al., 2012; Xiang et al.,
2013). Emerging pharmacological studies have revealed that
SBP displays pleiotropic roles in protecting the cardiovascular
system, as seen by the promotion of angiogenesis, amelioration of
inflammation, improvement of endothelium dysfunction, mitigation
of dyslipidemia, repression of vascular smooth muscle cell
proliferation, and migration and restraint of cardiac remodeling
(Lu et al., 2018).
On the mechanistic level, SBP has been shown to promote
angiogenesis by stimulating proliferation, migration, and nitric
oxide (NO) secretion by endothelial progenitor cells (Wu et al.,
2009). According to a recent meta-analysis of 25 studies with 439
animals, SBP was shown to reduce myocardial infarction area
through an increase of vascular endothelial growth factor (VEGF)
andmicrovessel count in CHD, indicating that SBP’s cardioprotective
effects are largely due to promotion of angiogenesis (Zhang et al.,
2017). In a rabbit model of myocardial infarction, administration of
SBP enhances angiogenesis in the infarcted area, whilst reducing
capillary density at the atherosclerotic plaque site in animal models at
the same time (Shen et al., 2010). In a previous study, one of us has
shown that the mixture of several compounds can show much the
same effects compared to the SBP extract by analyzing microarray
data (Fang et al., 2017). In this study, we tested the hypothesis that a
limited number of compounds found in SBP can synergistically
interact with each other to play amajor role in treating cardiovascular
diseases by promoting angiogenesis. Therapeutic angiogenesis is a
heavily investigated and promising method for treatment of
refractory angina or myocardial ischemia, among other indications
(Attanasio and Schaer, 2011; Mitsos et al., 2012).
In order to investigate the pro-angiogenic effect of SBP and to
understand its mechanism of action further, suitable model
systems are needed. Endothelial cells (ECs) are the principal
players involved in angiogenesis, and their ability to divide and
differentiate into tube-like structures in vitro has long been a
strong indicator of their key role in physiological and pathological
angiogenesis (Munoz-Chapuli et al., 2004) and thus, ECs can be
used in an in vitro model to study angiogenesis. ECs are highly
responsive to signals such as VEGF and fibroblast growth factors
(FGFs) (Carmeliet and Jain, 2011). The pro-angiogenic response
often involves multiple steps, including Akt activation (Fang
et al., 2013) as well as activation of its downstream target,
endothelial nitric oxide synthase (eNOS). NO release is one of
the first events in the angiogenic cascade, preceding new lumen
formation and even tip cell migration (Carmeliet and Jain, 2011).
On the other hand, the mitogen-activated protein kinase (MAPK)
pathway increases apoptotic pathway activated by environmental
stressors that downregulates the pro-angiogenic VEGF pathway
to mediate angiogenesis (Gomes and Rockwell, 2008), and
accompanies serum-starved apoptosis in ECs (Yilmaz et al.,
2003).
Human umbilical vein endothelial cells (HUVECs) are the
most commonly used in vitro models of angiogenesis, where it is
possible to observe their migration, proliferation and tubule
formation in response to exogenous inhibitory or stimulatory
agents (Staton et al., 2004). Overall, based on previous studies
above, their frequent use as a model system, and their ability to
recapitulate biologically relevant pathways (DeCicco-Skinner
et al., 2014), we chose HUVECs in this work to untangle some
aspects of the mode of action of angiogenesis modulators.
In a related study we modeled 22 chemicals identified in blood
plasma after oral administration of SBP, and their ability in pairwise
combinations to promote angiogenesis in vitro (Zobir et al.,
submitted). Here we systematically developed an algorithm to
predict the synergy of all 231 pairwise combinations of those 22
compounds, which was also successfully experimentally validated. It
was proposed from this previous work based on and in silico target
prediction model that certain complementary pathways are
responsible for the synergistic effect in promoting HUVEC
proliferation. From the compound side, ginsenoside Rb2 in
combination with ginsenoside Rg3 was found to dramatically
increase proliferation of HUVECs, and protected these cells
against homocysteine-induced damage. However, this previous
study did not experimentally validate molecular mechanisms that
caused those pro-angiogenic effects for this compound combination.
Hence, the present study aims to investigate the underlying
mechanisms of the combination of ginsenosides Rg2 and Rg3 by
utilizing RNA-sequencing (RNA-Seq) data generated in a
biologically relevant system. The mRNA readout was analyzed
by two standard methods in the field, namelyWeighted Gene Co-
expression Network Analysis (WGCNA) (Langfelder and
Horvath, 2008) and Gene Set Enrichment Analysis (GSEA)
(Subramanian et al., 2005), followed by expression validation
using qPCR. In addition, we used pathway inhibitors to
successfully verify the hypothesized modes of action, and
applied phenotypic assays to further elucidate the mechanisms
of this compound combination related to their modulation of
angiogenic processes.
MATERIALS AND METHODS
General Materials and Cell Culture
Ginsenosides
Ginsenoside Rb2 (purity >99.0%) was supplied by Shanghai
Hutchison Pharmaceuticals Ltd. (Shanghai, China) (Fang
et al., 2017), and ginsenoside Rg3 with >98.0% purity was
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supplied by Prof. Yeong Shik Kim, Seoul National University,
Republic of Korea (Ha et al., 2007). Compounds were dissolved to
100 mM in DMSO, then subsequently diluted in media. The final
concentration of DMSO was less than 0.1%, which is not toxic to
cells, and the vehicle control also contained the same amount of
DMSO as the compound solution to identify any solvent-induced
effects.
Cells and Biological Tools
HUVECs and human dermal fibroblasts (HDFs) were purchased
from PromoCell (Heidelberg, Germany). Cells were cultured in
PromoCell’s Endothelial Cell Growth Medium 2 (EGM-2)
containing 2% FBS, human epidermal growth factor (EGF),
human basic fibroblast growth factor (FGF), insulin-like
growth factor (IGF), human vascular endothelial growth factor
165 (VEGF165), ascorbic acid and heparin. Trypsin 0.005%/
EDTA 0.01% solution, Dulbecco A phosphate buffered saline
(PBS) and 1-Step™ NBT/BCIP (Pierce Protein Research) were
obtained from Thermo Fisher Scientific (MA, U.S.A.). Fetal
bovine serum (FBS), dimethyl sulfoxide (DMSO),
paraformaldehyde, Triton® X-100, rabbit anti-human von
Willebrand factor antibody (F-3520), and mouse anti-rabbit
IgG-alkaline phosphatase (A9919) were purchased from
Sigma-Aldrich (Gillingham, United Kingdom). Human
recombinant VEGF and precast gels were obtained from
Invitrogen Life Technologies (Paisley, United Kingdom) and
antibodies for Western blotting were sourced from Cell
Signaling through New England Biolabs (Hitchin,
United Kingdom).
Cell Viability Measurement
The effect of compounds and compound combinations on cell
proliferation in vitro was assessed by the Cell Counting Kit-8
(CCK-8) assay (Dojindo, Kumamoto, Japan). CCK-8 utilizes the
highly water-soluble tetrazolium salt WST-8, and
dehydrogenases within living cells reduce WST-8 to produce
colored (orange) formazan. The amount of formazan dye
generated is then proportional to the number of living cells.
HUVECs were seeded onto 96-well flat-bottom plates at a
density of 2.5 × 103 cells per well in 100 µl of EGM-2. Following
incubation for 24 h, the culture medium was aspirated and
replaced with diluted drug solutions or vehicle controls in
Endothelial Cell Basal Medium 2 (EBM-2, PromoCell).
Combinations of ginsenoside Rb2 (10, 50, 100 µM) and
ginsenoside Rg3 (1, 5, 10 µM) were treated in a 4 × 4
checkerboard arrangement allowing synergy to be quantified,
and therefore the best pair of concentrations of each compound
can be determined (Hsieh et al., 1993; Orhan et al., 2005; Vlot
et al., 2019). After incubation for a further 72 h, 10 μL of CCK-8
(Dijindo) was added to each well, and plates were incubated for
2 h in darkness at 37°C. Absorbance at 450 nmwas thenmeasured
with a MultiSkan Ascent Plate Reader (MTX LAB SYSTEMS,
Florida, U.S.A).
For sulforhodamine B (SRB) assay, HUVECs were treated
with drug solutions or vehicle controls under the same culture
condition as above. After 72 h of incubation, media was removed
and then cells were fixed in cold 3% Trichloroacetic acid (TCA)
for 30 min at 4°C. 0.057% SRB in 1% acetic acid were added to the
cells and images were captured. The ImageJ software was used to
count cell numbers present in each image.
Bliss Independence Model Measurement
The combination response (4 × 4) matrix contained percentages
of cell growth, with cell growth without compound treatment set
to 100%. Since the compounds applied either individually or in
combination are assumed to promote cell growth, each value in
the matrix was subtracted from 100 to produce percentage cell
growth starting from 0%. A single-compound dose response
curve was fitted to the data using the 4-parameter log-logistic
function (4-PL) with the Synergy Finder package in R (R
Development Core Team, 2010; He et al., 2018). Subsequently,
the synergy of the combination was calculated using the Bliss
model (Bliss, 1939), which assumes the drugs to act via
independent mechanisms (For a discussion of the theoretical
background and advantages and disadvantages of the different
synergy models see a recent review (Vlot et al., 2019)). The Bliss
score of the combination was calculated by averaging the
difference between the actual percentage of cell growth and
the expected percentage of cell growth with four replicate
values, also in Synergy Finder.
IncuCyte Time-Lapse Imaging
Images were acquired with the IncuCyte Live Cell Imaging
microscopy (Essen Bioscience) every 3 h up to 72 h under cell
culture conditions with a 10X objective. Averaged cell confluence
was calculated from three random fields of view per well using the
IncuCyte in-built algorithm. Relative confluence values were
obtained by normalizing each value to the time zero value in
each sample.
Homocysteine-Induced Damage in a
Co-culture Tube Formation Assay
The tube formation assay used here is based on the Bishop Model
of co-culture tube formation (Bishop et al., 1999). Briefly,
HUVECs and HDFs were cultured in EGM-2 until sub-
confluent. Cells were then seeded in 48-well flat-bottom plates
at a 1:20 ratio at around 2,000 HUVECs to 40,000 HDFs per well
in EGM-2 medium. After two days, media were replenished, and
on day 4, to allow for detection of protective effects of drugs
against homocysteine (HCY)-induced damage, EGM-2 was
titrated 10-fold with its basal medium (EBM-2) and 2% FBS.
After 4 h of incubation with ginsenoside Rb2 (50 µM) alone,
ginsenoside Rg3 (5 µM) alone, or the Rb2/Rg3 combination
showing the highest Biliss synergy score, 2 mM HCY was
added. These reagents in fresh media were replenished every
two days before staining on day 12.
For staining, cells were first fixed and permeabilized with 4%
paraformaldehyde in PBS, and an anti-human-vWF monoclonal
antibody (dilution ratio 1:1,000; Sigma-Aldrich, MO, U.S.A.) was
added (dilution ration 1:1,000) for 1 h before staining with an
anti-rabbit alkaline phosphatase conjugated antibody (dilution
ratio 1:1,000) for 45 min. The 1-Step™ NBT/BCIP (Thermo
Fisher Scientific, MA, U.S.A) was applied until a suitable
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signal was developed (10–15 min). Images of two fields of view
were taken for three wells each, and total tube area measured
using the ImageJ software. Total tube area was calculated as the
number of connected pixels using “Analyze particles” above a
certain size threshold (200-∞) following a binary normalization
with an automatic threshold level.
RNA-Sequencing
Total RNA was isolated from cells using the RNeasy Kit (Qiagen)
according to the manufacturer’s protocol. An additional DNase1
digestion step was performed to ensure that the samples were not
contaminated with genomic DNA. One microgram of total RNA,
after validation by an Agilent Bioanalyser 2,100 system to have an
appropriate RIN between 7.6–10, was used for library construction
using Illumina’s TruSeq Stranded mRNA Library Prep Kit (Illumina,
CA, U.S.A) at the Institute of Metabolic Science Genomics and
Transcriptomics Core Facility (Cambridge, United Kingdom).
Messenger RNA was enriched by poly-T oligo attached magnetic
beads before reverse transcription. Addition of a single “A” nucleotide
(adenylation) after the synthesis of the double-stranded cDNA
stopped the ligation of DNA fragments during the adapter
ligation reaction. Unique barcodes were added to individual
samples allowing multiplexed sequencing. DNA fragments with
successful adapters ligated were enriched with a limited
amplification. The second strand cDNA, with the incorporation of
dUTP, was quenched during amplification to allow strand-specific
sequencing. Indexed libraries were purified, normalized, pooled and
sequenced on the Illumina HiSeq 4,000 platform at single read length
of 50 base pairs at the Genomics Core Facility, Cancer Research
United Kingdom Cambridge Institute (Cambridge,
United Kingdom). The raw count data can be found at the
following link. https://www.ncbi.nlm.nih.gov/Traces/study/?
accPRJNA671806.
Analysis of Differentially Expressed Genes
The quality of the reads was examined using FastQC (Andrews,
2010) and Trimmomatic (Bolger et al., 2014). An index for the
reference genome, GRCh38 (Kersey et al., 2016) was created using
Bowtie2 (Langmead and Salzberg, 2012). Reads were then
mapped to the reference genome using Tophat2 (Kim et al.,
2013) with the --b2-very-sensitive option. HTSeq-0.6 (Anders
et al., 2015) was used to count the number of reads sorted by read
name using SAMtools (Li et al., 2009). Differentially expressed
genes (DEGs) between the untreated control and compound-
treated groups were estimated using the DESeq2 statistical
package (Love et al., 2014) with significant genes defined as
those with a False Discovery Rate (FDR) ≤0.01.
Weighted Correlation Network Analysis
The reads were matched to genes using the AnnotationDbi (Pagès
et al., 2018) and org.Hs.eg.db (Carlson, 2019) packages in R
(version 3.5.1) (R Core Team, 2018). Genes with zero variance
across all samples (control as well as Rb2, Rg3, Rb2+Rg3 and
FGF-treated) were removed. The remaining samples were
hierarchically clustered using average linkage and Euclidean
distance across all genes in R using the “wgcna” package
(Langfelder and Horvath, 2008). The unsigned network was
built using correlation of genes with the parameters softpower
β  10, mergeCutHeight  0.15, detectCutHeight  0.995, and
maxBlockHeight  32,000. Module size has a positive correlation
with Zsummary, a score that determines module preservation
(Langfelder et al., 2011). Choosing a larger number of similarly
sized modules allows for a fair comparison of the modules, and
hence was used for subsequent analysis. A Fisher’s Exact Test was
performed in WGCNA package to measure the categorical
overlap between the resultant modules. Module preservation
and reproducibility were determined using a permutation of
the inner- and intra-connectivity, eigengenes and densities
between the compound induced and control networks
(Langfelder et al., 2011), resulting in Zsummary scores and
median ranks. A previously suggested cutoff (Langfelder et al.,
2011) of Zsummary scores >10 for strong evidence of
conservation was applied, and 15 modules were excluded as
these were not significantly conserved when compared to the
control group (and so are assumed to represent unperturbed
biological mechanisms). Genes were filtered for intramodular
correlation (>0.7) and significance (<0.01) to focus on genes that
are central to the modules, in the connectivity space. In this
manner, the remaining genes are significantly correlated to the
module, and so increases the likelihood that they are assigned to
the correct module.
Gene Set and Pathway Analysis
Gene sets were analyzed using DAVID v 6.8 (Huang et al., 2009b; a)
to determine enriched Gene Ontology (GO) Biological Processes of
differentially expressed genes in the combination-treated group,
compared to control and highly enriched pathways (p value
<0.05) were identified with their constituent genes. DAVID
analysis was conducted under medium stringency for biological
process enrichment (Category: GOTERM_BP_DIRECT) and
annotation clusters were summarized manually for representation
purposes. To detect overrepresentation of genes in canonical
pathways, differentially expressed genes were compared to the
background of all measure genes. Genesets used were the
Molecular Signatures database v 6.1 (Subramanian et al., 2005)
(http://www.broadinstitute.org/gsea/msigdb/index.jsp), and overlap
of genes in a pathway level interaction network was conducted
with the ConsensusPathDB release 30 (January 09, 2015).
Quantitative Real Time PCR
A manually selected subset of genes of particular interest
originating from the above analyses (pathway annotation and
WGCNA analysis of RNA-seq results) were validated
experimentally through quantitative real-time polymerase
chain reaction (qPCR). Specific primers for selected genes
were designed according to literature (Supplementary Table
S2). All samples were amplified in triplicates and RNA utilized
for real-time qPCR was extracted with RNeasy as described
above. Purified RNA was reverse transcribed using the
iScript™ cDNA Synthesis Kit (BIO-RAD) following the
manufacturer protocol. Real time PCR amplifications were
performed in Quantstudio 5 (Thermo Fisher Scientific, MA,
U.S.A.) with an initial hot start of 95°C for 15 min followed by
45 cycles of 95°C for 15 s and 60°C for 30 s. In order to normalize
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qPCR reactions, GAPDH (Glyceraldehyde 3-phosphate
dehydrogenase) was included as housekeeping gene. The
relative expression of genes was calculated based on the
average Ct values across samples and significance was
determined using the Students t-test (Microsoft Excel 2019,
Microsoft, WA, U.S.A.), comparing control vs. the
combination-treated mean values.
Western Blotting
Western blots were performed on HUVECs grown in 6-well
plates. Following 30 min of incubation with drug or vehicle total
cell protein was harvested using a lysis buffer (50 mM Tris-HCl,
pH 7.5, 250 mM NaCl, 5 mM EDTA, 50 mM sodium fluoride,
0.5% sodium deoxycholate, 0.5% Triton X-100, protease inhibitor
cocktail) and protein concentration was measured using the BCA
Protein Assay Kit (Pierce Protein Research, Thermo Fisher
Scientific, MA, U.S.A.). Equal amounts of protein were loaded
into a 4–12% Bis-Tris gel (Invitrogen, Paisley United Kingdom)
before being transferred onto a nitrocellulose membrane
(Thermo Fisher Scientific, MA, U.S.A.). The membranes were
blocked in TBS-T + 5% milk and then stained using primary
antibodies (dilution ratio 1:1,000) overnight at 4°C, or at room
temperature for 1 h with gentle shaking in TBS-T solution.
Following three washes, horseradish peroxidase-conjugated
secondary antibody (rabbit anti-mouse, 1:5,000) was added for
1 h at room temperature with gentle shaking. The signal was
developed using Amersham ECL Prime (GE Healthcare,
Buckinghamshire United Kingdom).
Statistical Analysis
An ordinary one-way ANOVA with a Tukey’s multiple
comparisons test or a non-parametric Kruskal–Wallis one-way
analysis was performed on cell-based in vitro data using
GraphPad Prism version five for Windows (GraphPad
Software, CA, USA, www.graphpad.com), where the mean of
each treatment group was compared with the mean of the control.
p < 0.05 were considered as statistically significant.
RESULTS
Synergistic Effects of Ginsenosides Rb2
and Rg3 on Promoting Endothelial Cell
Proliferation
We first sought to characterize the effects of each single ginsenoside
on HUVEC proliferation to determine the optimal concentration
range for experiments. Since ginsenoside Rg3 is known to show cell
cytotoxicity at higher doses and thus widely used in cancer
treatments (Joo et al., 2015), we decided to use concentrations of
10–100 µM for ginsenoside Rb2 and 1–10 µM for ginsenoside Rg3
individually as well as in a 4 × 4 concentration matrix (Figure 1).
On the left side, individual effects of ginsenoside Rb2 or ginsenoside
Rg3 on HUVEC proliferation were shown. Both compounds have
enhancing effects over the basal growth, notably ginsenoside Rg3
promotes cell proliferation from 20% at 1 μM to 120% at 10 μM,
whereas ginsenoside Rb2 produced a weaker proliferating effect,
showing a sigmoidal curve. On the right side of Figure 1, the
percentage of the increase in cell proliferation can be seen in a
checkerboard format with concentrations of each compound on X
and Y axis. A Bliss (Bliss, 1939) synergy score of 39.48 was obtained
in combination-treated cells (Figure 1) which strongly supported
that ginsenoside Rb2 and ginsenoside Rg3 synergistically promote
endothelial cell proliferation. A Bliss synergy score above 0 indicates
synergism throughout the pairwise concentrations tested, thus
39.48 provides strong support to suggest that ginsenoside Rb2
and ginsenoside Rg3 can be a good combination in terms of
promoting endothelial cell proliferation.
FIGURE 1 | Effect of individual ginsenosides Rg3 and Rb2 on cell growth on a semi-logarithmic plot (left) and the 4 × 4 combination response matrix (right). By
calculating the synergy score with the Bliss method, ginsenoside Rb2 and ginsenoside Rg3 synergistically promoted endothelial cell growth with a Bliss synergy score of
39.48. Data are represented as mean ± SD, n  4.
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To investigate the time course of the synergistic effects of the
combination of ginsenosides Rb2 (50 µM) and Rg3 (5 µM) on
HUVEC growth, the IncuCyte system was used to track
confluency changes. Since drugs were dissolved in medium
without growth factors and nutrients the cell growth rate in
the control wells was slightly decreased over time (Figure 2A).
On the other hand, it was found that the cell population was
increased 2-fold at 72 h compared to time zero by the
combination of both ginsenosides, compared to either single
agent or vehicle control (with p < 0.001, Figure 2). The results
show that the combination of ginsenosides Rb2 and Rg3 can act
like a replacement for essential growth supplements to promote
cell proliferation when HUVECs are starved.
To addmore convincing results, the SRB assay data were included
in Figure 2. Representative images of stained cells after washout of
floating cells in each group were shown in Figure 2B. Notably, the
combination of Rb2 50 µM and Rg3 5 µM significantly promoted
HUVEC cell growth (Figure 2C). The CCK-8 assay, the IncuCyte
Live Cell Imaging and the SRB array differ in how they count the cell
number, therefore the readouts of each method can vary. From the
collection of obtained results, it is confirmed that the combination
showed ability to increase cell growth compared to either the vehicle
control or the single treated group.
Ginsenosides Rb2 and Rg3 Protect Human
Umbilical Vein Endothelial Cells Against
Homocysteine-Induced Damage in a
Co-culture Tube Formation Model
We next investigated the ability of endothelial cells to remodel and
align via an in vitro tube formation assay, which is a requirement for
the formation of new blood vessels during angiogenesis (Bishop et al.,
1999). This method follows the interactions between endothelial cells
and fibroblasts over 12 days leading to formation of vascular tubes
with lumen and varying lengths, and is hence considered a better
proxy (Gagnon et al., 2002) for the in vivo situation than the 6-h
Matrigel method (Staton et al., 2004). Adding HCY to this co-culture
tube formation model enables us to predict the ability of drugs to
protect blood vessels against damage elicited by
hyperhomocysteinemia. In the vehicle control group, co-culture of
HUVECs and fibroblasts successfully formed vascular tubes which
look like black thread, whilst 2 mMHCY destructed them. However,
FIGURE 2 | Effect of ginsenosides Rg3 and Rb2 on HUVEC proliferation as monitored by confluence of cell images every 3 h up to 90 h (A). The mean fold change
in confluence from the vehicle or compound alone or combination-treated group is shown. Confluence is a suitable surrogate for proliferation and cell growth over time,
until the point that cells are densely packed. It can be seen that the combination of these ginsenosides approximately doubled the cell growth rate over individual
treatments, and even more over control (no treatment). The representative images of SRB stained cells were shown (B). The ImageJ software was used to count
the number of stained cells and as a result the combination significantly increased cell counts (C). Data represents mean ± SD, n  4. * indicates p < 0.05 and *** indicates
significance at p < 0.001 (based on the Kruskal-Wallis non-parametric test).
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when the positive control FGF was treated before HCY induction,
tube-like structures were still formed, indicating FGF had ability to
protect HCY-induced vascular damage (Figure 3). Likewise, the
combination of 50 μM ginsenoside Rb2 and 5 μM ginsenoside
Rg3 (with highest Bliss synergy) clearly protected HUVEC tube-
like structures against 2 mM HCY-induced damage and hence
reversed the damaged phenotype. Quantitative measure of areas of
tube-like structures was conducted to confirm the protective effect of
the combination and presented as a bar graph in Figure 3.
Distinct Gene Expression Patterns of
Human Umbilical Vein Endothelial Cells
Treated With Ginsenosides Rb2 and Rg3
We next analyzed the gene expression profile of HUVECs
treated with either ginsenoside Rb2 (50 µM), ginsenoside Rg3
(5 µM) or Rb2/Rg3 combination in comparison to vehicle
control in order to elucidate the mechanistic basis of
compound synergy. This analysis resulted in 377 and 45
significantly differently expressed genes (DEGs; FDR <0.01)
in the combination-treated group and the ginsenoside Rb2-
treated group, respectively, compared to control, while no
significant DEGs was observed on treatment of Rg3. Hence, on
the overall level, when ginsenosides Rb2 and Rg3 are applied
jointly, many more genes are altered than the sum of genes
perturbed by the individual ginsenoside treatments,
indicating compound interactions beyond simple additivity.
The 377 DEGs in the combination-treated cells were next
subjected to Gene Set Enrichment Analysis (Subramanian et al.,
2005), and the resulting ten highly enriched pathways with lowest
p value are presented in Table 1. Extracellular matrix-related
pathways are seen to be differentially regulated, indicating the
pro-angiogenic effects by ginsenoside Rb2/Rg3 are at least
partially due to extracellular matrix modulation (Sottile, 2004).
FIGURE 3 | The combination of ginsenosides Rb2 and Rg3 protected endothelial cell tube against homocysteine (HCY)-induced damage in a co-culture tube
formation model. The protective effect of the ginsenoside Rb2/Rg3 combination was as good as the positive control FGF. Data represents mean ± SD (n  3). ###
indicates p < 0.001; ** indicates p < 0.01 for treatment rescue compared to homocysteine-induced damage (based on tukey’s one-way ANOVA).
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Next, we conducted Consensus PathDB (Kamburov et al.,
2013) for the 377 DEGs to obtain an alternative view on this
information, such as interactions between pathways. The 10 most
highly enriched pathways are listed in Table 2 and visualized as a
pathway level interaction network in Figure 4. Highly enriched
pathways can be seen to be associated with cell growth and cell
differentiation such as the EGFR, PDGFR and AP1 pathways,
which hence form the mode of action hypothesis for angiogenesis
modulation based on this part of the analysis. Ginsenoside Rb2
has been reported to promote epidermal proliferation via
enhancing EGFR-related growth factors (Choi, 2002). Given
that EGFR and PDGF are known receptors to promote
angiogenesis, and AP1 families are important transcription
factors to increase cell proliferation, we expect that the
combination of ginsenoside Rb2 and Rg3 may target one or
more of these pathways to produce overall effects.
Weighted Gene Correlation Network
Analysis
Initially, all cases datasets–FGF treated positive control, individual
Rb2 and Rg3 treatments, Rb2/Rg3 combination treatment and
vehicle control - were hierarchically clustered in gene expression
space (shown in Supplementary Figure S1). This separated FGF-
induced cells from the others, suggesting a separate mode-of-action,
which was to be expected as a positive control.
We next applied WGCNA to create modules of co-expressed
genes for the combination-treated group and tested these
modules based on their conservation against control networks,
the results of which are shown in Supplementary Table S1. 78
modules were found to not be conserved against control.
Networks were created for each condition and modules
formed at four levels, with each level representing cutting the
tree at different heights (Supplementary Figure S2). Level 4, the
lowest cut level, contained the large number (93) of distinct and
specific modules compared to the other levels (which provided
56, 52, and 38 modules, respectively). The white module was both
perturbed (i.e. not conserved) and contained the largest number
of DEGs (Supplementary Figure S3). The combination of genes
that are both differentially expressed and that are co-expressed (in
the same module) could suggest the genes mutual involvement in
the mode-of-action. Hence the white module was selected for
further study.
All modules were then annotated with GO terms and, for
example, the white module was found to have “angiogenesis (GO:
0001525)” among its significant terms (Table 3). As shown in
Figure 5, we conducted DESeq2 and WGCNA in parallel using
RNA-seq data. By WGCNA, we found modules that shared no co-
expression networks between control and treated groups and created
96modules (deep split3) for the control and the combination groups.
As a result, the white module showed the most significantly different
co-expression between two groups (Seumois et al., 2016). In Table 4,
the first six genes were selected because they were suggested by the
WGCNA method with GO annotation (White GO module), while
the remaining 12 genes were identified by DESeq2 in combination
with either GSEA or CPDB pathway analysis.
Genes related to angiogenesis and cell proliferation and
migration (GO terms GO:0001525, GO:0090050, GO:0008543),
from the white module were selected for further study since they
are most related to the observed activities we are interested in. Six
genes from the white module have been suggested as central genes
(high and significant correlation to module average) (Table 4),
and five of them, except SERPINE1, are only suggested by
WGCNA, (i.e. are not differentially expressed compared to
control in an enriched gene set). In total, 18 genes were
selected for further study (Table 4). We can see that different









k/K3 p-value FDR q-value
NABA_MATRISOME 1,028 Ensemble of genes encoding extracellular
matrix and extracellular matrix-associated proteins
49 0.0477 2.42 × 10−24 3.22 × 10−21
REACTOME_HEMOSTASIS 466 Genes involved in hemostasis 26 0.0558 5.76 × 10−15 3.65 × 10−12
NABA_MATRISOME_ASSOCIATED 753 Ensemble of genes encoding ECM-associated
proteins including ECM-affiliated proteins, ECM
regulators and secreted factors
32 0.0425 8.24 × 10−15 3.65 × 10−12
KEGG_FOCAL_ADHESION 201 Focal adhesion 17 0.0846 4.27 × 10−13 1.42 × 10−10
PID_FRA_PATHWAY 37 Validated transcriptional targets of AP1
family members Fra1 and Fra2
9 0.2432 8.65 × 10−12 2.30 × 10−9
NABA_SECRETED_FACTORS 344 Genes encoding secreted soluble factors 19 0.0552 3.32 × 10−11 7.36 × 10−9
KEGG_CYTOKINE_CYTOKINE_
RECEPTOR_INTERACTION
267 Cytokine-cytokine receptor interaction 17 0.0637 4.03 × 10−11 7.65 × 10−9
NABA_CORE_MATRISOME 275 Ensemble of genes encoding core extracellular
matrix including ECM glycoproteins, collagens
and proteoglycans
17 0.0618 6.39 × 10−11 1.06 × 10−8
KEGG_PATHWAYS_IN_CANCER 328 Pathways in cancer 18 0.0549 1.22 × 10−10 1.81 × 10−8
PID_INTEGRIN3_PATHWAY 43 Beta3 integrin cell surface interactions 8 0.186 1.28 × 10−9 1.71 × 10−7
1total number of genes in each gene set (K)
2number of genes of our DEGs in each gene set (k)
3ratio of k to K
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 6187738
Choi et al. Ginsenosides Rb2+Rg3 Promotes Angiogenic Phenotype
methods did not suggest entirely overlapping genes, for instance,
only 10 DEGs are highly and significantly correlated in the white
module. Thus, combining DEG andWGCNA approaches enables
to search potential genetic biomarkers which may be overlooked
when using only one method.
Gene Expression Analysis of Ginsenoside
Rb2/Rg3 Combination Treatment Based on
RNA-Seq and qPCR Data
We next performed quantitative polymerase chain reaction
(qPCR) on the 18 selected genes (Table 4) after the
combination treatment of ginsenoside Rb2 (50 µM) and Rg3
(5 µM). The quantitative fold change between the control and
the combination-treated cells of mRNA expression as well as the
result of RNA-Seq raw counts of the 18 genes were presented in
Figure 6. Notably, when compared with vehicle control, we can
confirm that mRNA expression of CXCL8, CYR61, FGF16 and
FGFRL1 was highly up-regulated by the Rb2/Rg3 combination.
The Ginsenoside Rb2/Rg3 Combination
Acts via the CXCR1/2 CXCL8 (IL8)-Mediated
PI3K/Akt and MAPK/ERK Signaling
Pathways
To further explore the molecular basis of the pro-proliferative
effect of the ginsenoside Rb2/Rg3 combination in HUVECs, the
CXCR1/2 antagonist Reparixin, the ERK inhibitor U0126 and the
PI3K inhibitor LY294002 were used to block their respective
signaling cascades. U0126, a kinase inhibitor of ERK to prevent
phosphorylation of ERK, a family of MAPK, has been used in
HUVEC at 10 µM in order to prove that their candidate drug
TABLE 2 |Overrepresentation analysis using Consensus PathDB comparing differentially expressed genes in ginsenoside Rb2/Rg3 combination treated cells to control (10
pathways with lowest p-value are shown). Growth factor-involved signaling pathways, such as PDGF, EGFR1 and differentiation pathway, are overrepresented aswell as
cell survival pathways such as AP1, senescence and autophagy in cancer.
p-value q-value Pathway Source
1.44 × 10−7 0.000149 Validated transcriptional targets of AP1 family members Fra1 and Fra2 Pathway interaction database (PID) Schaefer et al. (2009)
8.07 × 10−7 0.000417 Senescence and autophagy in cancer Wikipathways Kelder et al. (2009)
3.34 × 10−6 0.000856 AGE-RAGE signaling pathway in diabetic complications - homo sapiens (human) KEGG Kanehisa and Goto (2000)
3.96 × 10−6 0.000856 PDGF receptor signaling network PID
4.15 × 10−6 0.000856 Hypertrophy model Wikipathways
5.11 × 10−6 0.000879 Beta3 integrin cell surface interactions PID
6.06 × 10−6 0.000893 EGFR1 NetPath Kandasamy et al. (2010)
1.20 × 10−5 0.00143 Differentiation pathway Wikipathways
1.25 × 10−5 0.00143 Nuclear receptors meta-pathway Wikipathways
1.44 × 10−5 0.00143 Lung fibrosis Wikipathways
FIGURE 4 | Pathway level interaction network of 10 highly enriched pathways in the ginsenoside Rb2/Rg3 combination-treated cells annotated according to
ConsensusPathDB compared to control, providing synergy hypotheses of the compound combination. Node size is based on number of genes represented in each
pathway gene set, color is determined by statistical enrichment value (darker blue  higher p value) and edge thickness represents the total number of genes shared
between each pathway. (Detailed information about each pathway and its p value can be seen in Table 2.) It can be seen that growth factor receptor-mediated
pathways such as EGFR1 and PDGF are major signaling that may contribute promoting effects on endothelial cell proliferation. Also, other pathways which are AP1,
autophagy differentiation pathways are also known to be involved in regulating cell growth.
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induces angiogenesis via MAPK pathways (Wu et al., 2015).
LY294002 blocks PI3K activity that phosphorylates Akt, resulting
in unphosphorylated form of Akt. In this way we were able to test
the hypothesis, based on mRNA analysis, that CYR61-stimulated
IL-8 production leads to stimulation of the CXCR1/2 receptor,
and thus the PI3K/Akt and MAPK/ERK signaling pathways are
initiated consequently. The results of this experiment are shown
in Figures 7A–C and demonstrate that the Rb2/Rg3-induced
increase of HUVEC proliferation was significantly reduced in all
three cases (and most pronouncedly by Reparixin), indicating
that activation of CXCR1/2, MAPK/ERK and PI3K/Akt are
involved in the mode of action of the combination. Western
blot results (Figure 7D) demonstrated that Rb2/Rg3-induced Akt
and ERK phosphorylation was significantly suppressed by
LY294002 and U0126, while there was no reduction in the
amount of total Akt and ERK protein present. This indicates
that the activation of Akt and ERK via phosphorylation is also
involved in the mode of action of the ginsenoside Rb2/Rg3
combination when stimulating HUVEC proliferation.
DISCUSSION
Shexiang Baoxin pill (SBP), which consists of sevenmateriamedica, is
widely used as a TCM formulation for the treatment of coronary
heart disease. However, the modes of action of SBP in promoting
angiogenesis have not yet been fully understood. In this regards, we
previously modeled compound interactions of 22 constituent
compounds detected in plasma (Zobir et al., submitted). However,
while being able to predict synergies with a satisfactory performance
and suggesting modes of action of compounds, this previous work
did not biologically investigatemechanisms of synergistic interactions
between compounds in promoting angiogenesis. Here, we focused on
one particular combination of ginsenosides from SBPwhich has been
identified as synergistic, that of ginsenosides Rb2 and Rg3, in order to
investigate its molecular mode of action associated with angiogenesis.
Ginsenosides, isolated from Panax ginseng, are classified into two
groups of saponins according to chemical structure: the dammarane-
type having a 20(S)-protopanaxadiol/triol skeleton, and the oleanolic
acid type possessing an oleanolic acid skeleton. Ginsenoside Rb2 and
its hydrolytic product ginsenoside Rg3 belong to the protopanaxadiol
type of dammarane ginsenosides. Ginsenosides Rb2 and Rg3 have
multiple functions in immune regulation, anti-oxidation, anti-
inflammation, anti-aging and anti-fatigue (Choi, 2002; Choi et al.,
2015; Joo et al., 2015; Kim et al., 2016; Sun et al., 2017). However, their
pro-angiogenic effects have not been vigorously studied, while their
anti-angiogenesis along with anti-tumorigenic effects have been
shown in several cancers (Mochizuki et al., 1995; Joo et al., 2015;
Sun et al., 2016; Sun et al., 2017). As one of the few examples, related
to pro-angiogenic effects, Kim et al. reported that ginsenoside Rg3 at
1, 5, 10 µM was able to prevent INS-1 cell death by increasing cell
proliferation (Kim et al., 2016). Likewise, in our experimental
conditions using HUVECs, ginsenoside Rg3 at lower
concentrations (below 10 μM) markedly increased HUVEC
proliferation. It is notable that most of the anticancer effects of
TABLE 3 |Gene Ontology analysis of Biological Processes of 94 genes found in the White Module, which is not conserved with the control network and contains the highest
number of differentially expressed genes that correlated highly with the modules. It shows that this module is enriched in cell survival and angiogenesis signaling
pathways, and hence these genes are of significant interest in determining the combination mode of action.
Term Description p-value
GO:0097191 Extrinsic apoptotic signaling pathway 0.0147
GO:0001525 Angiogenesis 0.0169
GO:0090050 Positive regulation of cell migration involved in sprouting angiogenesis 0.0304
GO:0008152 Metabolic process 0.0380
GO:0097105 Presynaptic membrane assembly 0.0390
GO:0070886 Positive regulation of calcineurin-NFAT signaling cascade 0.0390
GO:0043085 Positive regulation of catalytic activity 0.0496
FIGURE 5 |Workflow of the RNA-sequencing (RNA-Seq) analysis for the
ginsenoside Rb2/Rg3 combination, compared to the control group. Firstly
(left), differentially expressed genes were determined using DESeq2. The 377
differentially expressed genes in the combination-treated group were
subject to Gene Set Enrichment Analysis (GSEA) and Consensus Path DB
(CPDB) gene set analyses. In parallel (right), Weighted Gene Co-expression
Network Analysis (WGCNA) was performed on combination treated vs
untreated cells, and the resulting white gene module was subject to Gene
Ontology and pathway analysis. Both methods together were used to
understand the synergistic effect of the ginsenoside combination treatment on
a mechanistic level, and formed the basis of selecting 18 genes for further
experimental validation by qPCR and Western blotting.
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ginsenoside Rg3 have been observed at much higher concentrations
(>25 μM, although it varies on cell type). In addition, ginsenoside Rb2
has been reported that to enhance cell proliferation and migration by
increasing EGF and EGFR levels (Choi, 2002). Given that
ginsenosides have steroid-like structures, they are likely to bind to
multiple steroid hormone receptors whichmay explain angiogenesis-
modulating effects (Leung and Wong, 2010). Mechanisms of
angiogenic activity of the saponin fraction has been proposed
mainly through enhancement of tissue-type plasminogen activator
(tPA) secretion together with suppression of plasminogen activator
inhibitor-1 (PAI-1) secretion (Morisaki et al., 1995). Morisaki et al.
reasoned that ginsenosides resembling sterols may contribute to the
angiogenic activity of saponin (Morisaki et al., 1995). Even though the
effect of these ginsenosides under different conditions (cell/tissue
type, concentration, etc.) is yet to be understood in detail, it is evident
that they target angiogenesis, and hence this work aimed to
understand the mode of action of two synergistic components of
a relevant traditional Chinese medicine, SBP, in this context.
While most of combination therapy aims at inhibiting
angiogenesis in cancer treatments, combination pharmacotherapy
can also provide benefits to prevent cardiovascular disease both in
patients with high risk factors and individuals with existing
TABLE 4 | List of 18 genes selected from preceding analyses for confirmation by qPCR. The first six genes were suggested by the WGCNA method with GO annotation
(White GO module), while the remaining 12 genes were identified by DESeq2 in combination with either GSEA or CPDB pathway analysis. Five genes (CIB1, MMP2,
TNFRSF12A, FGF16, FGFRL1) have been chosen by the WGCNA method only and not by DESeq2, indicating those genes from the most highly correlated module may still
be important in angiogenesis pathways, despite not being significantly differentially expressed.
Gene symbol Gene name Module Evidence
CIB1 Calcium and integrin binding 1 White White GO
MMP2 Matrix metallopeptidase 2 White White GO
SERPINE1 Serpin family E member 1 White White GO/GSEA/CPDB
TNFRSF12A TNF receptor superfamily member 12A White White GO
FGF16 Fibroblast growth factor 16 White White GO
FGFRL1 Fibroblast growth factor receptor-like 1 White White GO
SPARC Secreted protein acidic and cysteine rich Purple GSEA
PDGFA Platelet derived growth factor subunit A palevioletred3 GSEA/CPDB
SMOC1 SPARC related modular calcium binding 1 palevioletred2 GSEA
GDF3 Growth differentiation factor 3 navajowhite2 GSEA
TGFBR2 Transforming growth factor beta receptor 2 Lightyellow GSEA/CPDB
PDGFRB Platelet derived growth factor receptor beta Darkmagenta GSEA/CPDB
CYR61 Cysteine rich angiogenic inducer 61 Darkgrey GSEA/CPDB
ITGB1 Integrin subunit beta 1 Black GSEA
PDGFC Platelet derived growth factor C Black GSEA
SLIT3 Slit guidance ligand 3 antiquewhite4 GSEA
IL8(CXCL8) C-X-C motif chemokine ligand 8 Steelblue GSEA/CPDB
EDN1 Endothelin 1 Steelblue CPDB
FIGURE 6 | Elevation of mRNA expression in HUVECs treated with the combination of ginsenoside Rb2 (50 μM) and ginsenoside Rg3 (5 μM) or vehicle for 72 h as
determined by real time qPCR (in gray) and compared to RNA-Seq data (in black). It can be seen that the Rb2/Rg3 combination upregulated several genes by 2- to 3-
fold, such as CXCL8, CYR61, FGF16 and FGFRL1. Data represents mean ± SD of four replicates. *p < 0.05, **p < 0.01, ***p < 0.001.
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 61877311
Choi et al. Ginsenosides Rb2+Rg3 Promotes Angiogenic Phenotype
cardiovascular disease (Working Group on the Summit on
Combination Therapy for CVD et al., 2014). Our data
demonstrate that a combination of ginsenosides Rb2 and Rg3
may act synergistically in promoting cellular proliferation as well
as protecting endothelial cells from HCY-induced vascular damage.
Ginsenoside Rb1, one of the protopanaxadiol type dammarane
ginsenosides, has previously been shown to block HCY-induced
endothelial dysfunction in porcine coronary arteries, suggesting
potential clinical applications of ginsenosides in HCY-associated
vascular injuries (Zhou et al., 2005). In our co-culture model of
vascular tube formation, neither ginsenoside Rb2 alone nor
ginsenoside Rg3 alone at the chosen concentrations was sufficient
to rescue the tubes from HCY-induced damage; however, when
combining these two ginsenosides together, the tube damage was
largely reversed. The concentrations we used for the combination
treatment were based on the Bliss synergy and the endothelial cell
growth curves of each ginsenosides. Either ginsenoside Rb2 or
ginsenoside Rg3 alone was able to show sigmoidal curves where
the highest concentration hits plateau. Although synergism was
observed throughout the areas of combination-treatments,
ginsenoside Rb2 at 50 μM combined with ginsenoside Rg3 at
5 μMseem to be the best pair when compared to the single treatment.
In parallel with the potential therapeutic effects on reversing
HCY-induced damage, the current study demonstrates that the
ginsenoside Rb2/Rg3 combination can synergistically promote
HUVEC proliferation. To elucidate the underlying molecular
mechanism of the combination, RNA-Seq analysis of
differentially expressed genes (DEGs) has been conducted in
the present study. DEG analysis is a common method for
identifying genes that play an important role in phenotypic
effects, while transcription factor modifications such as
reversible phosphorylation and missense mutations can be
overlooked (Langfelder et al., 2011). Therefore, WGCNA
together with DEG approaches have been applied in order to
understand the mode of action of the compound combination
further. A total of 377 Rb2/Rg3-induced DEGs were found to be
highly enriched with angiogenesis- and extracellular matrix-
related pathways. Moreover, the module with highest overlap
of highly correlating DEGs and not conserved with control by
WGCNA was associated with angiogenesis-related biological
processes, however identifying somewhat distinct individual
genes, indicating the importance of using different analysis
methods in parallel. Since applications of RNA-Seq are not
completely known yet as according to the huge data generated,
researchers face challenges to analyze to avoid sequencing
artifacts. Therefore, combining two different tools provides us
more confident outcomes that those selected genes are less likely
artifacts but produced by meaningful biological processes.
Thus, in this study, we have provided the first evidence that
ginsenoside Rb2 and ginsenoside Rg3 synergistically promote
endothelial cell proliferation and protect them against HCY-
induced damage. RNA-Seq data by DEG and WGCNA
analysis further indicate that angiogenesis pathways are
transcriptionally perturbed by the combination of ginsenosides
Rb2 and Rg3. Confirmed by qPCR, Western blotting, and
pathway inhibition experiments, we hence conclude that the
Rb2/Rg3 combination promotes endothelial cell proliferation
through the CXCR1/2 CXCL8 (IL8)-mediated PI3K/Akt and
FIGURE 7 | Effects of selective inhibitors of Akt ((A); LY294002), CXCR1/2 ((B); Reparixin) and ERK ((C); U0126) on Rb2/Rg3-induced cell proliferation as
monitored by the CCK-8 assay, indicating the pro-proliferative effects of the combination were due to activation of at least those three pathways. The effect of the
CXCR1/2 inhibitor was most profound and entirely inhibited the stimulation of cell proliferation due to ginsenoside treatment. Data represents mean ± SD, n  4. **p <
0.005 and ###p < 0.001. (D) Phosphorylation of Akt and ERK by the combination of Rb2 and Rg3 in the presence or absence of LY294002 and U0126 as
measured by western blotting and the density of bands were measured. LY294002 and U0126 completely inhibited the promoting effects of Rb2 and Rg3 on the
phosphorylation of Akt and ERK, respectively. These results demonstrate that Akt and ERK, and their phosphorylation, are essential for the pro-proliferative effects of the
Rb2/Rg3 combination.
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MAPK/ERK signaling pathways (Heidemann et al., 2003) that
may further effects on promoting angiogenesis.
More generally, the present study suggests a protocol on how
to gain insight into the mode of action of a combination of two
compounds from an originally more complex herbal formulation,
which could be beneficial to standardize and simplify their
complexity while maintaining efficacy.
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